Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
IKT: Ordinary SharesTotal Employee Number:
35Compare
Compare
Traded in other countries / regions
IKT.USAIQT0.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2020-12-23Description
Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing small-molecule kinase inhibitors for neurodegenerative and infectious diseases. Its lead program, risvodetinib (IkT-148009), is an oral inhibitor of c-Abl kinase being developed for Parkinson's disease and other synucleinopathies, including multiple system atrophy. The company also has earlier-stage programs targeting protein kinases involved in viral infections, including infections of the central nervous system. Inhibikase's research is based on its proprietary kinase inhibitor platform, which it uses to design compounds intended to modify disease progression rather than only treat symptoms. The company operates as a single reporting segment and is headquartered in the United States. As a clinical-stage business, it has no approved products and generates no product revenue, funding its research and development through equity financings, grants, and partnership arrangements.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 51 | |||||
3-Year FCF Growth Rate | 59 | |||||
3-Year Book Growth Rate | -36 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.54 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.98 | |||||
9-Day RSI | 37.45 | |||||
14-Day RSI | 43.38 | |||||
3-1 Month Momentum % | 31.15 | |||||
6-1 Month Momentum % | 31.15 | |||||
12-1 Month Momentum % | 55.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.82 | |||||
Quick Ratio | 15.82 | |||||
Cash Ratio | 15.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -215.2 | |||||
Shareholder Yield % | -0.89 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -46.87 | |||||
ROA % | -44.16 | |||||
ROIC % | -1390.45 | |||||
3-Year ROIIC % | -563.5 | |||||
ROC (Joel Greenblatt) % | -74613.64 | |||||
ROCE % | -50.76 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.9 | |||||
Price-to-Tangible-Book | 1.9 | |||||
EV-to-EBIT | -3.65 | |||||
EV-to-Forward-EBIT | -0.08 | |||||
EV-to-EBITDA | -3.66 | |||||
EV-to-Forward-Revenue | 1358.04 | |||||
EV-to-FCF | -5.2 | |||||
| Price-to-Net-Current-Asset-Value | 1.91 | |||||
| Price-to-Net-Cash | 1.95 | |||||
Earnings Yield (Greenblatt) % | -27.4 | |||||
FCF Yield % | -13.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibikase Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.437 | ||
| Beta | 0.3297 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 0.99 | ||
| Volatility % | 67.61 | ||
| 14-Day RSI | 43.38 | ||
| 14-Day ATR ($) | 0.104562 | ||
| 20-Day SMA ($) | 2.4042 | ||
| 12-1 Month Momentum % | 55.84 | ||
| 52-Week Range ($) | 1.33 - 2.61 | ||
| Shares Outstanding (Mil) | 139.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibikase Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 53 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:50 | 2.41 (-0.82%) | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 2.41 (-0.82%) | ||
| General meeting for 2026 | 2026-06-26 16:00 | 1.87 (+0.54%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 2.03 (-1.93%) | ||
| Annual report for 2025 | 2026-03-26 | 1.63 (+1.87%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.63 (+1.87%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.60 (+0.63%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.71 (-3.39%) | ||
| General meeting for 2025 | 2025-06-27 16:00 | 1.65 (-0.60%) |
Show
Entries
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(IKT)'s stock price today?
The current price of IKT is $2.20. The 52 week high of IKT is $2.61 and 52 week low is $1.33.
When is next earnings date of Inhibikase Therapeutics Inc(IKT)?
The next earnings date of Inhibikase Therapeutics Inc(IKT) is 2026-11-13 Est..
Does Inhibikase Therapeutics Inc(IKT) pay dividends? If so, how much?
Inhibikase Therapeutics Inc(IKT) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers